Marcello Arca

Pubblicazioni

Titolo Pubblicato in Anno
Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial JOURNAL OF CLINICAL LIPIDOLOGY 2023
Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study THE LANCET REGIONAL HEALTH. EUROPE 2023
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance EUROPEAN HEART JOURNAL SUPPLEMENTS 2023
Clinical Approach in the Management of Paediatric Patients with Familial Hypercholesterolemia: A National Survey Conducted by the LIPIGEN Paediatric Group NUTRIENTS 2023
ANGPTL3 Deficiency and Risk of Hepatic Steatosis CIRCULATION 2023
[How to overcome barriers to implementation of prevention and management strategies of atherosclerotic cardiovascular disease through lipid-lowering therapy] GIORNALE ITALIANO DI CARDIOLOGIA 2023
Refinement of the diagnostic approach for the identification of children and adolescents affected by familial hypercholesterolemia: Evidence from the LIPIGEN study ATHEROSCLEROSIS 2023
Real‐World Effectiveness of PCSK9 Inhibitors in Reducing LDL‐C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE 2023
ANGPTL3 Deficiency and Risk of Hepatic Steatosis CIRCULATION 2023
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study THE LANCET 2022
The Fibrinogen-like Domain of ANGPTL3 Facilitates Lipolysis in 3T3-L1 Cells by Activating the Intracellular Erk Pathway BIOMOLECULES 2022
ANGPTL3 deficiency associates with the expansion of regulatory T cells with reduced lipid content ATHEROSCLEROSIS 2022
Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study FRONTIERS IN GENETICS 2022
Heterogeneity of non-alcoholic fatty liver disease (NAFLD): implication for cardiovascular risk stratification ATHEROSCLEROSIS 2022
Genetically determined deficiency of ANGPTL3 does not alter HDL ability to preserve endothelial homeostasis BIOCHIMICA AND BIOPHYSICA ACTA. MOLECULAR AND CELL BIOLOGY OF LIPIDS 2022
Twelve variants polygenic score for low-density lipoprotein cholesterol distribution in a large cohort of patients with clinically diagnosed familial hypercholesterolemia with or without causative mutations JOURNAL OF THE AMERICAN HEART ASSOCIATION. CARDIOVASCULAR AND CEREBROVASCULAR DISEASE 2022
Differential effects of bariatric surgery on plasma levels of ANGPTL3 and ANGPTL4 NMCD. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES 2022
Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY 2022
Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target HEART 2022
Is it Time for Single-Pill Combinations in Dyslipidemia? AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS 2022

Progetti di Ricerca

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma